377 related articles for article (PubMed ID: 34503094)
1. TP53 in Biology and Treatment of Osteosarcoma.
Synoradzki KJ; Bartnik E; Czarnecka AM; Fiedorowicz M; Firlej W; Brodziak A; Stasinska A; Rutkowski P; Grieb P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503094
[TBL] [Abstract][Full Text] [Related]
2. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
3. Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.
Hansen SA; Hart ML; Busi S; Parker T; Goerndt A; Jones K; Amos-Landgraf JM; Bryda EC
Dis Model Mech; 2016 Oct; 9(10):1139-1146. PubMed ID: 27528400
[TBL] [Abstract][Full Text] [Related]
4. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
Shaul E; Roth M; Lo Y; Geller DS; Hoang B; Yang R; Malkin D; Gorlick R; Gill J
Cancer; 2018 Mar; 124(6):1242-1250. PubMed ID: 29313943
[TBL] [Abstract][Full Text] [Related]
5. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
6. Modeling the Etiology of p53-mutated Cancer Cells.
Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
[TBL] [Abstract][Full Text] [Related]
7. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Saleh A; Perets R
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
9. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
[No Abstract] [Full Text] [Related]
10. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
11.
Shin DY
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
[TBL] [Abstract][Full Text] [Related]
12. Targeting the DNA Damage Response in OSCC with TP53 Mutations.
Lindemann A; Takahashi H; Patel AA; Osman AA; Myers JN
J Dent Res; 2018 Jun; 97(6):635-644. PubMed ID: 29489434
[TBL] [Abstract][Full Text] [Related]
13. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
Li KW; Wang SH; Wei X; Hou YZ; Li ZH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
[TBL] [Abstract][Full Text] [Related]
15. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
16. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
17. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies.
Kaur RP; Vasudeva K; Kumar R; Munshi A
Curr Pharm Des; 2018; 24(30):3566-3575. PubMed ID: 30255744
[TBL] [Abstract][Full Text] [Related]
18. Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.
Lorenz S; Barøy T; Sun J; Nome T; Vodák D; Bryne JC; Håkelien AM; Fernandez-Cuesta L; Möhlendick B; Rieder H; Szuhai K; Zaikova O; Ahlquist TC; Thomassen GO; Skotheim RI; Lothe RA; Tarpey PS; Campbell P; Flanagan A; Myklebost O; Meza-Zepeda LA
Oncotarget; 2016 Feb; 7(5):5273-88. PubMed ID: 26672768
[TBL] [Abstract][Full Text] [Related]
19. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
[TBL] [Abstract][Full Text] [Related]
20. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]